Harvard Medical School, Boston, MA 02115, USA.
Expert Rev Vaccines. 2014 Apr;13(4):507-19. doi: 10.1586/14760584.2014.890053. Epub 2014 Feb 27.
Despite the recognition of Pseudomonas aeruginosa as an opportunistic pathogen, no vaccine against this bacteria has come to market. This review describes the current state-of-the-art in vaccinology for this bacterium. This includes a discussion of those at risk for infection, the types of vaccines and the approaches for empirical and targeted antigen selection under development, as well as a perspective on where the field should go. In addition, the challenges in developing a vaccine for those individuals at risk are discussed.
尽管铜绿假单胞菌已被确认为一种机会性病原体,但目前尚无针对该细菌的疫苗上市。本综述描述了该细菌疫苗学的最新进展。这包括对感染风险人群的讨论、疫苗类型以及正在开发的经验性和靶向性抗原选择方法,以及对该领域未来发展方向的展望。此外,还讨论了为处于感染风险中的个体开发疫苗所面临的挑战。